Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;5:103. doi: 10.1038/s41698-021-00238-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Crown 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Sagittal (left) and axial (middle) post-contrast MRI and concurrent PET/CT (right) images prior to nivolumab therapy (top panel) demonstrate an enhancing solid mass involving the clivus, basiocciput and right occipital condyle (arrows), with effacement of the premedullary cistern and indentation upon the brainstem (arrowheads) and a large focus of metabolic activity at the tumour site (SUVmax 8.2; arrow). Follow-up images (lower panels) 3 months after the initiation of nivolumab therapy show substantial decrease in size of the mass (arrows), with resolution of mass effect upon the brainstem. The concurrent PET/CT image shows attendant decrease in the region of metabolic activity (SUVmax 6.0; arrow), indicating a partial radiographic response. b Target lesion size at baseline and following 3, 7, 11 and 14 cycles of nivolumab.